Document is current
Any future updates will be listed below
-
Authors
Gregoire, Nicolas
Marchand, Sandrine
Barbier, François
Quenot, Jean-Pierre
Herbrecht, Jean-Etienne
Roux, Damien
Landais, Mickaël
Schnell, David
Veinstein, Anne
Dahyot-Fizelier, Claire
Vourc’h, Nathalie Heuzé
Respaud, Renaud
Tavernier, Elsa
Ehrmann, Stephan
,
,
-
Funding
Funding for this research was provided by:
French ministry of health (PHRC-15-260)
- License Information
-
More Information
Article History
Received: 12 January 2026
Accepted: 19 March 2026
First Online: 2 April 2026
Declarations
:
: The trial protocol, including pharmacokinetic analyses was approved by a national ethics committee (comité de protection des personnes Ouest I, no. 2016-R29), all patients provided written informed consent in accordance with French law and the Declaration of Helsinki.
: Not applicable.
: FB declares lecture fees from MSD and Advanz Pharma, consulting fees from Shionogi, conference invitation from Pfizer, and research grant from MSD and Aerogen. SE declares consultancies, travel support, lecture fees for Aerogen Ltd, travel support and lecture fees for Fisher & Paykel Healthcare, and intellectual property licensed to JIB smart home.
